drugset

drugset / Trial / NCT00330707

Combined Use of BCG and Interferon Alpha in Bladder Cancer

NCT00330707 ↗

Phase 2/3 Completed 140 enrolled National University Hospital, Singapore National Medical Research Council (NMRC), Singapore · collab

RandomizedSingle-groupDouble-blindTreatment

Summary

To compare the toxicity and efficacy of the combination of BCG and interferon alpha to standard dose and low dose BCG alone in high risk superficial bladder cancer

Timeline

Start: 1995-10
Primary completion: —
Completion: 2005-06

Publications

Chiong E, Kesavan A, Mahendran R, Chan YH, Sng JH, Lim YK, Kamaraj R, Tan TM, Esuvaranathan K. NRAMP1 and hGPX1 gene polymorphism and response to bacillus Calmette-Guerin therapy for bladder cancer. Eur Urol. 2011 Mar;59(3):430-7. doi: 10.1016/j.eururo.2010.11.031. Epub 2010 Dec 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bacillus Calmette-Guérin	Vaccine	27 mg	Intrathecal
Subject	Bacillus Calmette-Guérin	Vaccine	81 mg	Intrathecal
Subject	interferon alfa-2b	Protein / enzyme biologic	—	Intrathecal

Indications